Literature DB >> 17904132

Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas.

Andrew Flood1, Volker Mai, Ruth Pfeiffer, Lisa Kahle, Alan T Remaley, Elaine Lanza, Arthur Schatzkin.   

Abstract

BACKGROUND & AIMS: Indicators of insulin resistance have been hypothesized to promote colorectal cancer.
METHODS: We assayed fasting serum from 375 subjects with and 375 subjects without a recurrent adenoma during the course of the Polyp Prevention Trial to determine baseline concentrations of insulin and glucose, as well as changes in these measurements over the course of 4 years of follow-up evaluation. To estimate the relative risk of adenoma recurrence for each of these serum measures, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable logistic regression models adjusting for age, sex, body mass index, intervention group, and an interaction term for sex and intervention group.
RESULTS: For both insulin and glucose, we found higher risk for subjects in the high quartile compared with the low quartile (OR, 1.56; 95% CI, 1.00-2.43 for insulin; OR, 1.49; 95% CI, 0.95-2.31 for glucose). The association for glucose was most apparent for advanced adenomas (OR, 2.43; 95% CI, 1.23-4.79) but for insulin, we did not observe this pattern. When we restricted the analysis to those without a family history of colorectal cancer, we observed an even stronger association between increased glucose at study entry and adenoma recurrence (OR, 1.78; 95% CI, 1.06-3.01 for all adenomas; OR, 3.52; 95% CI, 1.47-8.42 for advanced adenoma).
CONCLUSIONS: Our findings suggest that patients with increased insulin and glucose are at higher risk of adenoma recurrence, and for those with increased glucose, the increase in risk for recurrence of advanced adenomas is even greater.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904132     DOI: 10.1053/j.gastro.2007.08.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Insulin resistance, central obesity, and risk of colorectal adenomas.

Authors:  Ana Patricia Ortiz; Cheryl L Thompson; Amitabh Chak; Nathan A Berger; Li Li
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 2.  Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.

Authors:  Susan Storey; Diane Von Ah; Marilyn J Hammer
Journal:  Oncol Nurs Forum       Date:  2017-07-01       Impact factor: 2.172

3.  Diabetes and risk of incident colorectal cancer in a prospective cohort of women.

Authors:  Andrew Flood; Lori Strayer; Catherine Schairer; Arthur Schatzkin
Journal:  Cancer Causes Control       Date:  2010-04-10       Impact factor: 2.506

4.  Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.

Authors:  M Barba; F Sperati; S Stranges; C Carlomagno; G Nasti; V Iaffaioli; G Caolo; M Mottolese; G Botti; I Terrenato; P Vici; D Serpico; A Giordano; G D'Aiuto; A Crispo; M Montella; G Capurso; G Delle Fave; B Fuhrman; C Botti; S De Placido
Journal:  Ann Oncol       Date:  2011-11-18       Impact factor: 32.976

5.  Lack of association between insulin sensitivity and colorectal adenoma risk.

Authors:  Rebecca L Sedjo; Ralph B D'Agostino; Dennis Ahnen; Theodore R Levin; Steven M Haffner; Janet A Tooze; Tim Byers
Journal:  Nutr Cancer       Date:  2011       Impact factor: 2.900

6.  High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.

Authors:  Yi-Shing Ma; I-Ping Yang; Hsiang-Lin Tsai; Ching-Wen Huang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

7.  Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer.

Authors:  J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-03-05       Impact factor: 5.554

Review 8.  Metabolic syndrome and cancer.

Authors:  Pooja Pothiwala; Sushil K Jain; Subhashini Yaturu
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

9.  Components of metabolic syndrome and metachronous colorectal neoplasia.

Authors:  Erin L Ashbeck; Elizabeth T Jacobs; María Elena Martínez; Eugene W Gerner; Peter Lance; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-24       Impact factor: 4.254

10.  Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity.

Authors:  Hendrik J F Helmerhorst; Katrien Wijndaele; Søren Brage; Nicholas J Wareham; Ulf Ekelund
Journal:  Diabetes       Date:  2009-05-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.